Clinical trial

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2014-06-01

PhasePHASE2 / PHASE3

Study timeline

Study start (unknown)2014-06-01Date precision: month

Registry last updated2024-05-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

NaBen®DRUG

PlaceboDRUG

Sponsors & collaborators

SyneuRx International (Taiwan) Corplead sponsor

Mapped research locations

TaipeiTaiwan2 BaltimoreMaryland, United States1 AtlantaGeorgia, United States1 MiamiFlorida, United States1 San AntonioTexas, United States1 ClevelandOhio, United States1 CincinnatiOhio, United States1 Washington D.C.District of Columbia, United States1 MinneapolisMinnesota, United States1 Ann ArborMichigan, United States1 RochesterNew York, United States1 Long BeachCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01908192 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.